ALT-801 Phase 1/2 Clinical Trial Is Enrolling Relapsed Or Refractory Myeloma Patients - The Florida-based biopharmaceutical company Altor Bioscience has started a Phase 1/2 clinical trial of its investigational drug ALT-801.  The trial is being conducted at the University of Iowa and is recruiting myeloma patients who have had at least two previous treatment regimens.  ALT-801 is a protein that triggers immune cells to attack cancer cells.  The drug also is being explored as a potential treatment for melanoma and …

Additional results from a Phase 3 study show that Xgeva may be more effective than Zometa in treating bone disease in multiple myeloma patients. Specifically, Xgeva was better than Zometa in reducing bone fractures, limiting the need for bone radiation treatment, and preventing the worsening of pain in cancer patients with bone disease.

Despite these findings, physicians are likely to remain cautious about treating myeloma patients with Xgeva, as there are concerns about the drug's safety when used in myeloma …

Final results from a Phase 2 study show that Kyprolis can be an effective treat­ment for re­lapsed and refractory multiple myeloma patients, with nearly a quarter of these patients responding to treat­ment.

Dr. David Siegel, from the John Theurer Cancer Center and lead investigator of the study, said the results dem­onstrate that Kyprolis (car­filz­o­mib) has “excellent activity with low toxicity.”

Based on the results of this study, the U.S. Food and Drug Administration recently approved Kyprolis for use in …